Bile acids and Barrett's oesophagus: A sine qua non or coincidence?

Scandinavian Journal of Gastroenterology

Volumn 41, Issue SUPPL. 243, 2006, Pages 11-17

  Sital, Rudy ^a   Kusters, Johannes ^a   De Rooij, Felix ^a   Kuipers, Ernst ^a   Siersema, Peter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; Barrett's oesophagus; Bile acids; Bilitec 2000 monitoring; Deoxycholic acid; Dysplasia; Gastro oesophageal reflux disease; Oesophageal cancer; pH monitoring; Proton pump inhibitors

Indexed keywords

BILE ACID; CYCLOOXYGENASE 2; DEOXYCHOLIC ACID; OMEPRAZOLE; PROTON PUMP INHIBITOR; TAURINE; PROTON PUMP;

BARRETT ESOPHAGUS; CANCER GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE ASSOCIATION; DUODENOGASTRIC REFLUX; DUODENUM FLUID; ESOPHAGEAL ADENOCARCINOMA; HUMAN; PH MEASUREMENT; PRECANCER; PRIORITY JOURNAL; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; METABOLISM; PATHOPHYSIOLOGY; PH; REVIEW; SECRETION; STOMACH PH;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; CYCLOOXYGENASE 2; DUODENOGASTRIC REFLUX; ESOPHAGEAL NEOPLASMS; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; PROTON PUMPS;

EID: 33745395997     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600664219     Document Type: Conference Paper

References (53)

1. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-42.
2. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
3. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
4. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39:1175-9.
5. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and the esophagogastric junction. Gastroenterology 1993;104:510-3.
6. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
7. Oberg S, DeMeester TR, Peters JH, Hagen JA, Nigro JJ, DeMeester SR, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999;117:572-80.
8. Wakelin DE, Al-Mutawa T, Wendel C, Green C, Garewal HS, Fass R. A predictive model for length of Barrett's esophagus with hiatal hernia length and duration of esophageal acid exposure. Gastrointest Endosc 2003;58:350-5.
9. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
10. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
11. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070-4.
12. Jankowski JA, Harrison JF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000;16:356:2079-85.
13. Theisen J, Peters JH, Stein HJ. Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus. World J Surg 2003;27:1018-20.
14. Birgisson S, Rice TW, Easley KA, Richter JE. The lack of association between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Am J Gastroenterol 1997;92:216-21.
15. Parrilla P, Liron R, Martinez de Haro LF, Ortiz A, Molina J, De Andres B. Gastric surgery does not increase the risk of developing Barrett's esophagus. Am J Gastroenterol 1997;92:960-3.
16. Alexandrou A, Davis PA, Law S, Whooley BP, Murthy SC, Wong J. Esophageal cancer in patients with a history of distal gastrectomy. Arch Surg 2002;137:1238-42.
17. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Gastric surgery is not a risk for Barrett's esophagus or esophageal adenocarcinoma. Gastroenterology 2001;121:1281-5.
18. Marshall RE, Anggiansah A, Owen WA, Owen WJ. Investigation of oesophageal reflux symptoms after gastric surgery with combined pH and bilirubin monitoring. Br J Surg 1999;86:271-5.
19. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg 1995;82:657-60.
20. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. Ann Surg 1995;222:525-31.
21. Dixon MF, Neville PM, Mapstone NP, Moayyedi P, Axon AT. Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux? Gut Sep 2001;49:359-63.
22. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-9.
23. Mittal RK, Reuben A, Whitney JO, McCallum RW. Do bile acids reflux into the esophagus? A study in normal subjects and patients with gastroesophageal reflux disease. Gastroenterology 1987;92:371-5.
24. Gotley DC, Morgan AP, Cooper MJ. Bile acid concentrations in the refluxate of patients with reflux oesophagitis. Br J Surg 1988;75:587-90.
25. Gotley DC, Morgan AP, Ball D, Owen RW, Cooper MJ. Composition of gastro-oesophageal refluxate. Gut 1991;32:1093-9.
26. Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997;122:874-81.
27. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602.
28. Mirvish SS. Studies on experimental animals involving surgical procedures and/or nitrosamine treatment related to the etiology of esophageal adenocarcinoma. Cancer Lett 1997;117:161-74.
29. Clark GW, Smyrk TC, Mirvish SS, Anselmino M, Yamashita Y, Hinder RA, et al. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: an experimental rat model. Ann Surg Oncol 1994;1:252-61.
30. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996;224:358-70.
31. Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996;67:269-74.
32. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98:2120-8.
33. Kaur BS, Ouatu-Lascar R, Omary MB, Triadafilopoulos G. Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol 2000;278:G1000-9.
34. Siersema PD, Kaur BS, Toivola DM, Hofmann AF, Omary MB, Kuipers EJ, et al. Conjugated but not unconjugated bile acids induce time-dependent increases in proliferation in Barrett's esophagus ex vivo cultures. Gastroenterology 2004;126:A237.
35. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96.
36. 2 release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002;283:G327-34.
37. Buskens CJ, Ristimaki A, Offerhaus GJ, Richel DJ, van Lanschot JJ. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma. Scand J Gastroenterol 2003;Suppl 239:87-93.
38. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994;107:747-54.
39. Marshall RE, Anggiansah A, Manifold DK, Owen WA, Owen WJ. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut 1998;43:603-6.
40. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001;96:331-7.
41. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327-35.
42. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83.
43. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut. Oct 1999;45:489-94.
44. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
45. Hofmann AF. Chemistry and enterohepatic circulation of bile acids. Hepatology 1984;4 Suppl 5:4S-14S.
46. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001;15:511-21.
47. Shindo K, Machida M, Fukumura M, Koide K, Yamazaki R. Omeprazole induces altered bile acid metabolism. Gut 1998;42:266-71.
48. Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000;4:50-4.
49. Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001;121:1391-9.
50. Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174-80.
51. Jaiswal K, Tello V, Lopez-Guzman C, Nwariaku F, Anthony T, Sarosi GA Jr. Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. Surgery 2004;136:160-8.
52. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25:317-23.
53. Brasitus TA. Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology 1995;109:2036-8.